232 related articles for article (PubMed ID: 27666124)
1. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1.
Gao HX; Yan L; Li C; Zhao LM; Liu W
Mol Med Rep; 2016 Nov; 14(5):4135-4143. PubMed ID: 27666124
[TBL] [Abstract][Full Text] [Related]
2. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
3. MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator.
Jiao A; Sui M; Zhang L; Sun P; Geng D; Zhang W; Wang X; Li J
Mol Med Rep; 2016 Apr; 13(4):3349-55. PubMed ID: 26935975
[TBL] [Abstract][Full Text] [Related]
4. miR-200b/c targets the expression of RhoE and inhibits the proliferation and invasion of non-small cell lung cancer cells.
Tang Q; Li M; Chen L; Bi F; Xia H
Int J Oncol; 2018 Oct; 53(4):1732-1742. PubMed ID: 30066855
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
Kim HR; Kim WS; Choi YJ; Choi CM; Rho JK; Lee JC
Mol Oncol; 2013 Dec; 7(6):1093-102. PubMed ID: 23993685
[TBL] [Abstract][Full Text] [Related]
6. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
Wang X; Chen X; Wang R; Xiao P; Xu Z; Chen L; Hang W; Ruan A; Yang H; Zhang X
Oncol Rep; 2013 Aug; 30(2):643-50. PubMed ID: 23754305
[TBL] [Abstract][Full Text] [Related]
7. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.
Cuyàs E; Pérez-Sánchez A; Micol V; Menendez JA; Bosch-Barrera J
Cell Cycle; 2016 Dec; 15(24):3413-3418. PubMed ID: 27753543
[TBL] [Abstract][Full Text] [Related]
8. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
9. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
Wang M; Zhang R; Zhang S; Xu R; Yang Q
Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
[TBL] [Abstract][Full Text] [Related]
12. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
13. miRNA-124 modulates lung carcinoma cell migration and invasion.
Li Z; Wang X; Li W; Wu L; Chang L; Chen H
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):603-12. PubMed ID: 27251409
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.
Kurashige J; Kamohara H; Watanabe M; Hiyoshi Y; Iwatsuki M; Tanaka Y; Kinoshita K; Saito S; Baba Y; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S656-64. PubMed ID: 22311119
[TBL] [Abstract][Full Text] [Related]
15. Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes.
Zhao S; Zhang Y; Zheng X; Tu X; Li H; Chen J; Zang Y; Zhang J
J Cell Physiol; 2015 Nov; 230(11):2706-17. PubMed ID: 25808945
[TBL] [Abstract][Full Text] [Related]
16. miR-338-3p suppresses epithelial-mesenchymal transition and metastasis in human nonsmall cell lung cancer.
Hong-Yuan W; Xiao-Ping C
Indian J Cancer; 2015 Dec; 52 Suppl 3():E168-71. PubMed ID: 27453416
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
Fukuda K; Takeuchi S; Arai S; Katayama R; Nanjo S; Tanimoto A; Nishiyama A; Nakagawa T; Taniguchi H; Suzuki T; Yamada T; Nishihara H; Ninomiya H; Ishikawa Y; Baba S; Takeuchi K; Horiike A; Yanagitani N; Nishio M; Yano S
Cancer Res; 2019 Apr; 79(7):1658-1670. PubMed ID: 30737231
[TBL] [Abstract][Full Text] [Related]
18. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1.
Liu PL; Liu WL; Chang JM; Chen YH; Liu YP; Kuo HF; Hsieh CC; Ding YS; Chen WW; Chong IW
PLoS One; 2017; 12(7):e0180844. PubMed ID: 28727734
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
